HalcyGen works on IND
Friday, 18 July, 2008
Generic drugs company HalcyGen Pharmaceuticals [ASX: HGN] has completed recruitment and dosing for the first of three pharmacokinetic trials of its SUBA-Itraconazole anti-fungal agent.
The trials, part of the company's Investigational New Drug (IND) application for the product, will examine the absorption, distribution, metabolism and excretion of SUBA-Itraconazole.
It will compare SUBA-Itraconazole directly to the itraconazole market-leader Sporanox, which was developed by Johnson and Johnson subsidiary Janssen Pharmaceuticals.
According to HalcyGen, early trials of SUBA-Itraconazole have already demonstrated increased bioavailability compared to Sporanox.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
